Metraipolis › archive › dc_7ceed69eb903

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel… — Europe PMC PMID:41695071

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41695071
DOI: 10.1002/jpr3.70106
License (as archived): solo-consultazione
Archived: 2026-11-08T23:04:27.631Z
SHA-256 of the archived text: ece20fa0af5320b7914d5cb4b44ede722a1b3be07d2060da388bd5c5d8052489
Stable URL of this page: https://metraipolis.com/documento/dc_7ceed69eb903

How to cite

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel… — Europe PMC PMID:41695071 — Europe PMC (en), https://europepmc.org/article/MED/41695071 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7ceed69eb903 (Metraipolis archive dc_7ceed69eb903, sha256 ece20fa0af5320b7914d5cb4b44ede722a1b3be07d2060da388bd5c5d8052489)

BibTeX

@misc{dc7ceed69eb903,
  title = {Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel… — Europe PMC PMID:41695071},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41695071},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7ceed69eb903; sha256 ece20fa0af5320b7914d5cb4b44ede722a1b3be07d2060da388bd5c5d8052489},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41695071. Agents can read the archived copy with the MCP tool read_document.